In Vitro Susceptibility of Fusarium to Isavuconazole-Reference-Cited by-同舟云学术

In Vitro Susceptibility of Fusarium to Isavuconazole

Published:2020-01-27 Issue:2 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Broutin A.¹,Bigot J.²,Senghor Y.¹,Moreno-Sabater A.¹³,Guitard J.²,Hennequin C.²

Affiliation:

1. Service de Parasitologie-Mycologie, Assistance Publique-Hôpitaux de Paris, Hôpital St. Antoine, Paris, France

2. Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Paris, France

3. Sorbonne Université, INSERM U1135, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France

Abstract

To evaluate the in vitro susceptibility of Fusarium to isavuconazole, 75 clinical isolates were identified using matrix-assisted laser desorption ionization–time of flight mass spectrometry and then tested with a broth microdilution method (EUCAST) and the gradient concentration strip (GCS) technique. The activity of isavuconazole overall was shown to be limited, with an MIC 50 of >16 μg/ml, without significant differences between the species complexes.

Funder

Basilea Pharmaceutica

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01621-19

Reference30 articles.

1. Fusarium: Molecular Diversity and Intrinsic Drug Resistance

2. Phylogenetic relationships among members of the Fusarium solani species complex in human infections and the descriptions of F. keratoplasticum sp. nov. and F. petroliphilum stat. nov.

3. European Confederation of Medical Mycology (ECMM) epidemiological survey on invasive infections due to Fusarium species in Europe